Antibody drug conjugates (ADCs) are a class of drug therapies that combine the targeting abilities of monoclonal antibodies with the cancer-killing activities of cytotoxic agents. ADCs can…
From disease basics to insightful analysis of market dynamics, Heart Failure | Disease Landscape & Forecast | G7 provides comprehensive disease coverage addressing critical aspects of the heart…
Atopic Dermatitis | Emerging Therapies | Dupixent | US is a three-wave series that tracks the introduction of Sanofi/Regeneron’s Dupixent for the treatment of AD. The series is based on primary…
One of the most intriguing but administratively difficult trends in U.S. health insurers’ attempts to control the rising costs of prescription drugs is the use of outcomes-based contracting,…
Although the Alzheimer’s disease (AD) treatment paradigm is stable and most current treatments in the United States are generically available, several new therapies for AD, including the first…
Treatment of moderate to severe cancer pain will continue to be dominated by opioid analgesics for the foreseeable future. However, with the widespread epidemic of opioid abuse and misuse in the…
Recent and upcoming marketing authorizations and label expansions are increasing the therapy options for non-Hodgkin’s lymphoma (NHL). Despite a flourishing treatment armamentarium, tightening…
As of 2016, over 2 million people across the EU5 countries have a diagnosis of schizophrenia. Many of the oral atypical antipsychotic therapies used to treat the symptoms of schizophrenia are…
The HIV therapy market is growing as a result of the uptake of new premium-priced antiretroviral (ARV) agents, particularly the latest single-tablet regimens (STRs), which offer improved safety and…
In China, multiple myeloma treatment is centered on the use of three major agents—Janssen’s Velcade (bortezomib), Celgene’s Revlimid (lenalidomide), and thalidomide—while the treatment for…
The chronic heart failure therapy market is crowded and dominated by generics. In 2015 in the United States, the first new branded agents in more than 15 years entered that market. Using primary…
Nearly 23 million people across the EU5 suffer from major depressive disorder. Generic availability of a growing number of therapies has improved patient access to antidepressants and loosened…
Chronic kidney disease (CKD) is a general term for a set of heterogeneous disorders that negatively affect the function and structure of the kidney. CKD is characterized by a progressive loss of…
The maturing, but highly lucrative, market for multiple sclerosis (MS) disease-modifying therapies (DMTs) is becoming increasingly fragmented as attractive new options enter a powerful…
Chronic Hepatitis C (HCV) affects several thousand people in Brazil and Colombia. New therapies allow cure in a short period of time with minimal side effects, in contrast to older options. Brazil…